20-hour combination chemotherapy in advanced breast cancer.
نویسندگان
چکیده
منابع مشابه
CAF vs. CMF Combination Chemotherapy in Advanced Breast Cancer Patients
Breast cancer is the second most common neoplasm in women. There has been a modest increase in the duration of survival of most women with breast cancer. This increase in survival has come about because of the recognition that breast cancer is a systemic disease. Systemic nature is the driving force behind newer chemotherapeutic approaches. The purpose of this study was to determine the relativ...
متن کاملChemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
One hundred-forty-five postmenopausal women with metastatic breast cancer entered a prospective randomized trial comparing treatment A (cyclophosphamide, methotrexate, and 5-fluorouracil; CMF) with treatment B (the same chemotherapy plus tamoxifen; CMF plus T). Patients on treatment A had T added to CMF at the time of progression or relapse (second-line CMF plus T). One hundred thirty-three cas...
متن کاملPaclitaxel-based combination chemotherapy for breast cancer.
Clinical trials to develop paclitaxel (Taxol)-containing combinations started in 1992 with several approaches to combine doxorubicin and paclitaxel. Schedule-dependent toxicity limited doses in the initial trials, although antitumor activity was high. More recently, a well-tolerated, highly effective doxorubicin/paclitaxel regimen was developed with the use of bolus anthracycline administration...
متن کاملMGBG–cisplatin combination chemotherapy against breast cancer
Worldwide, it is estimated that more than one million women are diagnosed with breast cancer every year, representing 14% of female cancer deaths [1], about 4,500 new cases being detected each year in Portugal. In the present study, the compound metylglyoxal bis(guanylhydrazone) (MGBG) [2], an inhibitor of S-adenosylL-methionine descarboxylase (SAMdc), was investigated as a potencial anti-cance...
متن کاملFirst-Line Chemotherapy for Advanced Breast Cancer.
First-line chemotherapy for metastatic breast cancer has been the focus of ongoing controversy, a condition that partially reflects the imperfections of available therapy. It also partially reflects not only the imperfections in our ability to monitor response, but also the disagreements among clinicians over the goals of therapy. Each physician maintains a hierarchy of goals for the treatment ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1977
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.2.6094.1064